Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?

Detalles Bibliográficos
Autores principales: Szarvas, Tibor, Olah, Csilla, Reis, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797631/
https://www.ncbi.nlm.nih.gov/pubmed/35117093
http://dx.doi.org/10.21037/tcr.2019.01.05
_version_ 1784641598099816448
author Szarvas, Tibor
Olah, Csilla
Reis, Henning
author_facet Szarvas, Tibor
Olah, Csilla
Reis, Henning
author_sort Szarvas, Tibor
collection PubMed
description
format Online
Article
Text
id pubmed-8797631
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87976312022-02-02 Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes? Szarvas, Tibor Olah, Csilla Reis, Henning Transl Cancer Res Editorial AME Publishing Company 2019-03 /pmc/articles/PMC8797631/ /pubmed/35117093 http://dx.doi.org/10.21037/tcr.2019.01.05 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial
Szarvas, Tibor
Olah, Csilla
Reis, Henning
Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
title Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
title_full Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
title_fullStr Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
title_full_unstemmed Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
title_short Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
title_sort neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797631/
https://www.ncbi.nlm.nih.gov/pubmed/35117093
http://dx.doi.org/10.21037/tcr.2019.01.05
work_keys_str_mv AT szarvastibor neoadjuvantcisplatinbasedchemotherapyinprimaryandsecondarymuscleinvasivebladdercancerisitasurrogateformolecularsubtypes
AT olahcsilla neoadjuvantcisplatinbasedchemotherapyinprimaryandsecondarymuscleinvasivebladdercancerisitasurrogateformolecularsubtypes
AT reishenning neoadjuvantcisplatinbasedchemotherapyinprimaryandsecondarymuscleinvasivebladdercancerisitasurrogateformolecularsubtypes

Ejemplares similares